Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M84,852Revenue $M16,385Net Margin (%)16.6Z-Score5.2
Enterprise Value $M85,915EPS $1.5Operating Margin %17.5F-Score6
P/E(ttm))32.0Cash Flow Per Share $2.8Pre-tax Margin (%)19.3Higher ROA y-yY
Price/Book5.610-y EBITDA Growth Rate %1.7Quick Ratio1.6Cash flow > EarningsY
Price/Sales5.35-y EBITDA Growth Rate %-5.5Current Ratio1.8Lower Leverage y-yN
Price/Cash Flow11.7y-y EBITDA Growth Rate %165ROA % (ttm)7.5Higher Current Ratio y-yY
Dividend Yield %2.8Insider Buy (3m)0ROE % (ttm)17.9Less Shares Outstanding y-yN
Payout Ratio %89.0Shares Outstanding M1,657ROI % (ttm)5.7Gross Margin Increase y-yN

Gurus Latest Trades with BMY

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BMYVanguard Health Care Fund 2014-06-30 Add0.86%$46.59 - $52.19
($49.29)
$ 51.75%Add 22.96%36,197,961
BMYJoel Greenblatt 2014-06-30 Buy 0.05%$46.59 - $52.19
($49.29)
$ 51.75%New holding, 89363 sh.89,363
BMYRay Dalio 2014-06-30 Sold Out $46.59 - $52.19
($49.29)
$ 51.75%Sold Out0
BMYRonald Muhlenkamp 2014-03-31 Buy 1.9%$48.54 - $56.61
($53.23)
$ 51.7-3%New holding, 212015 sh.212,015
BMYVanguard Health Care Fund 2014-03-31 Add0.73%$48.54 - $56.61
($53.21)
$ 51.7-3%Add 20.35%29,437,761
BMYRay Dalio 2014-03-31 Buy $48.54 - $56.61
($53.23)
$ 51.7-3%New holding, 4428 sh.4,428
BMYGeorge Soros 2014-03-31 Sold Out -0.05%$48.54 - $56.61
($53.23)
$ 51.7-3%Sold Out0
BMYJoel Greenblatt 2014-03-31 Sold Out -0.02%$48.54 - $56.61
($53.23)
$ 51.7-3%Sold Out0
BMYJoel Greenblatt 2013-12-31 Buy 0.02%$46.41 - $53.84
($50.96)
$ 51.72%New holding, 11679 sh.11,679
BMYVanguard Health Care Fund 2013-09-30 Add0.64%$41.32 - $47.53
($43.84)
$ 51.718%Add 20.26%24,459,861
BMYJean-Marie Eveillard 2013-09-30 Reduce-0.01%$41.32 - $47.53
($43.84)
$ 51.718%Reduce -75.17%16,520
BMYVanguard Health Care Fund 2013-06-30 Add0.39%$39.68 - $47.68
($43.41)
$ 51.719%Add 13.32%20,338,461
BMYGeorge Soros 2013-06-30 Buy 0.05%$39.68 - $47.68
($43.41)
$ 51.719%New holding, 100000 sh.100,000
BMYJean-Marie Eveillard 2013-06-30 Add0.01%$39.68 - $47.68
($43.41)
$ 51.719%Add 302.66%66,520
BMYRay Dalio 2013-06-30 Sold Out -0.07%$39.68 - $47.68
($43.41)
$ 51.719%Sold Out0
BMYPrem Watsa 2013-06-30 Sold Out -0.01%$39.68 - $47.68
($43.41)
$ 51.719%Sold Out0
BMYVanguard Health Care Fund 2013-03-31 Add0.96%$32.59 - $41.19
($36.62)
$ 51.741%Add 49.53%17,948,561
BMYRay Dalio 2013-03-31 Add0.05%$32.59 - $41.19
($36.62)
$ 51.741%Add 267.87%181,140
BMYJohn Hussman 2013-03-31 Sold Out -0.64%$32.59 - $41.19
($36.62)
$ 51.741%Sold Out0
BMYJames Barrow 2013-03-31 Sold Out -0.05%$32.59 - $41.19
($36.62)
$ 51.741%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BMY is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
BMY Joel Greenblatt 2014-06-3089,3630.010.05New Buy
BMY Vanguard Health Care Fund 2014-06-3036,197,9612.184.6+22.96%
BMY Ronald Muhlenkamp 2014-06-30212,7700.011.8+0.36%
BMY Dodge & Cox 2014-06-3078,92100-0.25%
BMY Mario Gabelli 2014-06-30674,6850.040.17-1.76%
BMY Jean-Marie Eveillard 2014-06-3014,49200-12.28%
BMY Ray Dalio 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


BMY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Cuss Francis MEVP & CSO 2014-09-16Sell63,667$50.772.34view
Caforio GiovanniCOO 2014-09-15Sell26,691$49.874.19view
Caldarella Joseph CSVP & Controller 2014-09-10Sell7,415$51.031.82view
ANDREOTTI LAMBERTOCEO 2014-09-08Sell50,000$51.051.78view
von Autenried PaulSVP, Enterp. Services & CIO 2014-08-19Sell20,000$49.894.15view
Bancroft Charles AEVP & CFO 2014-07-29Sell67,621$51.061.76view
Moed Samuel JSVP, Strat Plan & Analysis 2014-07-28Sell25,752$49.325.35view
Caldarella Joseph CSVP & Controller 2014-03-13Sell9,137$55.2-5.87view
ANDREOTTI LAMBERTOCEO 2014-03-10Sell100,000$55.52-6.41view
Schmukler Louis SPres., Global Mfg. & Supply 2014-03-10Sell8,799$55.81-6.9view

Press Releases about BMY :

    Quarterly/Annual Reports about BMY:

    News about BMY:

    Articles On GuruFocus.com
    Bristol-Myers: Absolute Valuation Model versus Relative Valuation Model Aug 29 2014 
    Will ImmunoGen’s Q4 Earnings Disappoint Again? Jul 30 2014 
    UnitedHealth Group Up on Weak Day for the Dow Jul 17 2014 
    Pharma Sector Stocks To Consider For Sustained Returns Jun 25 2014 
    Johnson & Johnson (JNJ) Dividend Stock Analysis May 29 2014 
    A Look at AstraZeneca’s New Drug on Diabetes May 22 2014 
    Vanguard Health Care Fund's Top Quarterly Holdings Apr 30 2014 
    Abbvie Inc. (ABBV) Dividend Stock Analysis Mar 21 2014 
    Abbott Capturing Incremental Market Share Mar 18 2014 
    Vanguard Health Care Fund’s Top Five Feb 10 2014 


    More From Other Websites
    Cancer drug stocks on the move amid striking data Sep 29 2014
    European Medicines Agency Validates the Marketing Authorization Application for Nivolumab in... Sep 29 2014
    The Zacks Analyst Blog Highlights: Gilead Sciences, Bristol-Myers, Johnson & Johnson, AbbVie and... Sep 29 2014
    Bristol immune drug shows strong effect in melanoma study Sep 29 2014
    3:08 am Bristol-Myers reports positive Phase 3 data for Opdivo in advanced melanoma patients... Sep 29 2014
    Bristol immune drug shows strong effect in melanoma study Sep 29 2014
    Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with... Sep 29 2014
    Bristol immune drug shows strong effect in melanoma study Sep 29 2014
    [video] Fast Money Final Trade: XOM, HYG, YHOO & BMY Sep 26 2014
    Fast Money Final Trade: XOM, HYG, YHOO & BMY Sep 26 2014
    Bristol immunotherapy gets 6-month U.S. FDA review for melanoma Sep 26 2014
    Bristol immunotherapy gets 6-month U.S. FDA review for melanoma Sep 26 2014
    Bristol-Myers Squibb Announces Multiple Regulatory Milestones for Opdivo (nivolumab) in the U.S. and... Sep 26 2014
    Gilead's HIV Drugs Tybost and Vitekta Get FDA Clearance Sep 26 2014
    BMY, MRK And PFE, 3 Drugs Stocks Pushing The Industry Lower Sep 26 2014
    Cramer's Remix: Selloff strategies to survive drop Sep 25 2014
    Cramer's Bristol-Myers theorem: What is it? Sep 25 2014
    INNATE PHARMA: Third DSMB for EffiKIR trial recommends continuation as planned Sep 25 2014
    Gilead's New HIV Drug Key To Long-Term Strategy Sep 24 2014
    Bristol-Myers Squibb and Pfizer Announce Charitable Donations of More Than $1 Million to Support... Sep 22 2014
    BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in... Sep 19 2014
    Bristol-Myers' (BMY) Yervoy Label Expanded in Canada Sep 19 2014
    Merck Enters into Licensing Agreement with Sun Pharma Sep 18 2014
    French cancer immunotherapy specialist OSE Pharma prepares IPO Sep 18 2014
    [$$] Bristol-Myers CEO Sells $2.5 Million in Stock Sep 17 2014
    Bristol-Myers Squibb Announces Dividend Sep 16 2014
    FDA clears Eliquis for new use against blood clots Aug 21 2014
    AstraZeneca steps up push into cancer immunotherapy Jul 31 2014
    Bristol-Myers profit tops forecasts, helped by newer drugs Jul 24 2014
    Bristol 2Q net drops on lower drug sales, charges Jul 24 2014
    Bristol-Myers Squibb and Ono Pharmaceutical Co., Ltd. Announce Strategic Immuno-Oncology... Jul 23 2014
    Pfizer, Bristol clot drug wins EU green light for wider use Jun 27 2014
    Bristol-Myers says cancer drug met goal in study Jun 24 2014
    US slaps duties on steel pipes from Malaysia, Vietnam, Thailand Jun 24 2014
    Bayer faces law suits in United States over Xarelto - paper Jun 14 2014
    Bristol-Myers Squibb and Syngene International Extend Research Collaboration Jun 03 2014
    U.S. confirms duties on steel pipes from Malaysia, Vietnam, Thailand May 23 2014
    FDA to give blood cancer drug faster review May 19 2014
    Bristol-Myers slumps on cancer drug study data May 15 2014
    Celldex climbs on Bristol-Myers partnership May 14 2014
    Possible delay for Bristol cancer-drug causes jitters Apr 29 2014
    Bristol-Myers profit up 54 pct. on cost cuts, sale Apr 29 2014
    Bristol-Myers quarterly profit beats expectations as costs cut Apr 29 2014
    Bristol-Myers Squibb and Samsung BioLogics Expand Manufacturing Agreement Apr 22 2014
    Bristol-Myers Squibb and Samsung BioLogics Expand Manufacturing Agreement Apr 22 2014
    Reckitt leans towards pharmaceuticals spin-off Apr 16 2014
    In A Subanalysis, The Benefits Of Eliquis® (apixaban) Vs. Warfarin In Reducing The Risk Of Stroke... Mar 27 2014
    Bristol-Myers Squibb to Present Data for Daclatasvir in Multiple Investigational All-oral... Mar 24 2014
    Five Prime Therapeutics and Bristol-Myers Squibb Sign Collaboration Agreement to Discover Novel... Mar 17 2014
    Bristol-Myers in $50.5M deal with Five Prime Mar 17 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK